Bone Marrow Transplantation10.1038/sj.bmt.17041122003323293-298Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trialsJ T Horan, J L Liesveld, I D Fernandez, G H Lyman, G L Phillips, N B Lerner, S G Fisher,,
Biology of Blood and Marrow Transplantation10.1016/s1083-8791(00)70056-5200063309-320Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignanciesThomas R. Spitzer, Steven McAfee, Robert Sackstein, Christine Colby, Han Chong Toh, Pratik Multani, Susan Saidman, Dina Weymouth, Frederic Preffer, Cathleen Poliquin, Alicia Foley, Benjamin Cox, David Andrews, David H. Sachs, Megan Sykes,
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2005.11.169200612253-54Intentional induction of immune-hematopoietic mixed chimerism as a platform for early cellular therapy in pediatric leukemia patients after allogeneic transplantation: Enhancing GvL effect while avoiding GvHDM.A. Diaz, M. Ramirez, A. Perez-Martinez, M. Gonzalez-Vicent, J. Garcia-Castro, L. Madero,
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2017.07.007201723111989-1997Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or MaintainedLauren E. Caldemeyer, Luke P. Akard, John R. Edwards, Anand Tandra, Dawn R. Wagenknecht, Michael J. Dugan,
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2009.10.0322010161S57-S63HLA-Haploidentical Stem Cell Transplantation for Hematologic MalignanciesEphraim J. Fuchs, Xiao-jun Huang, Jeffrey S. Miller,
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2016.12.3272017233S375Safety of Preemptive Donor Lymphocyte Infusion Based on Mixed Chimerism (MC) in Peripheral Blood or Bone Marrow Subsets in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT) for Hematologic MalignanciesAngela Liou, Justin T. Wahlstrom, Christopher C. Dvorak, Biljana Horn,
Bone Marrow Research10.1155/2015/176526201520151-6Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic MalignanciesEmmanuel Levrat, Eddy Roosnek, Stavroula Masouridi, Bilal Mohty, Marc Ansari, Jean Villard, Jakob R. Passweg, Yves Chalandon,,
Bone Marrow Transplantation10.1038/sj.bmt.17018551999242201-204Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemiaMK Mital, A Curtis, V Spencer, D Barge, R Skinner,,
Biology of Blood and Marrow Transplantation10.1016/s1083-8791(03)00077-6200395320-329Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantationBimalangshu R Dey, Steven McAfee, Christine Colby, Robert Sackstein, Susan Saidman, Nancy Tarbell, David H Sachs, Megan Sykes, Thomas R Spitzer,
Biology of Blood and Marrow Transplantation10.1016/j.bbmt.2008.12.244200915279Stable Mixed Chimerism After Non-Myeloablative Transplant for Sickle Cell Disease: Normal Hematopoiesis Dominates Over Abnormal In Mixed ChimerismS. Ildstad, A. Cheerva, D. Tollerud, S. Bertolone, G. Herzig, R. Herzig,